Circulating CD3+CD4+CD161+ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma
Table 2
Univariate analyses of risk factors for the occurrence of mucositis, infection before engraftment, and CMV reactivation.
Variable
Mucositis (≥grade 3)
Infection before engraftment (CDI + MDI)
CMV reactivation
RR (95% CI)
RR (95% CI)
RR (95% CI)
Age (years), continuous
1.03 (0.98–1.09)
0.272
1.00 (0.95–1.04)
0.846
1.04 (0.99–1.11)
0.149
Sex (female versus male)
2.73 (1.14–6.53)
0.024
2.25 (1.02–4.95)
0.044
0.57 (0.23–1.40)
0.216
BMI (kg/m2), continuous
0.84 (0.72–0.99)
0.037
0.86 (0.75–0.99)
0.039
0.87 (0.75–1.02)
0.088
Diabetes (yes versus no)
0.46 (0.10–2.20)
0.330
1.10 (0.34–3.50)
0.878
1.85 (0.55–6.20)
0.319
Cr (mg/dl), continuous
1.10 (0.77–1.56)
0.617
1.59 (0.81–3.10)
0.178
1.15 (0.81–1.65)
0.433
GFR (ml/min/1.73 m2), continuous
0.98 (0.97–0.99)
0.006
0.99 (0.98–1.00)
0.096
1.00 (0.99–1.01)
0.450
Pulmonary
None-mild
1
1
1
Moderate
2.21 (0.79–6.19)
0.130
0.89 (0.37–2.12)
0.790
1.52 (0.55–4.19)
0.415
Severe
1.72 (0.52–5.71)
0.374
2.86 (0.97–8.42)
0.057
1.77 (0.56–5.55)
0.332
Hepatic
None
1
1
1
Mild
2.03 (0.65–6.32)
0.222
0.41 (0.13–1.30)
0.130
0.64 (0.17–2.47)
0.521
Moderate-severe
-
-
-
-
-
-
HCT-CI
0–4
1
1
1
≥4
0.89 (0.29–2.71)
0.836
3.44 (1.15–10.28)
0.027
0.89 (0.29–2.71)
0.836
Proportion of CD3+CD4+CD161+ cells (%), continuous
0.88 (0.76–1.02)
0.098
0.90 (0.80–1.00)
0.055
0.86 (0.73–1.00)
0.047
Proportion of CD3+CD8+CD161+ cells (%), continuous
0.99 (0.93–1.06)
0.781
0.97 (0.92–1.03)
0.352
0.94 (0.88–1.02)
0.129
BMI, body mass index; CDI, clinically defined infection; CI, confidence interval; CMV, cytomegalovirus; GFR, glomerular filtration rate; HCT-CI, hematopoietic cell transplantation comorbidity index; MDI, microbially defined infection; RR, relative risk. Modification of diet in renal disease (MDRD) GFR was used.
